CROI 2016 Program at a Glance

Program and Agenda

10:15 89LB Virus, Host, and Disease Factors Govern HIV-1 Broadly Neutralizing Antibody Induction

Session O-8 Oral Abstracts

Room 302

10:00 AM-12:00 PM Drugs: From Discovery to Challenges in Clinical Use Oral Abstract Moderators Peter L. Anderson ,UniversityofColorado,Denver,CO,USA Anne-Marie Taburet ,HôpitauxdeParis,HôpitauxUniversitairesParis-Sud,Le Kremlin-Bicêtre,France 10:00 96 Pharmacologic Measures of Adherence and Relationship to Drug Response Peter L. Anderson ,UnivofColorado,Denver,CO,USA 10:30 97 HIV-1 Combinectin BMS-986197: A Long-Acting Inhibitor With Multiple Modes of Action 10:45 98 Long-Acting Oral and Parenteral Dosing of MK-8591 for HIV Treatment or Prophylaxis Jay Grobler 1 ; Evan Friedman 2 ; Stephanie E. Barrett 1 ; Sandra L.Wood 1 ;Wendy Ankrom 1 ; Kerry L. Fillgrove 1 ; Ming-Tain Lai 1 ; Marian Gindy 1 ; Marian Iwamoto 3 ; Daria J. Hazuda 1 ; for the MK-8591 Early DevelopmentTeam 1 Merck&Co, Inc,WestPoint,PA,USA; 2 Merck&Co, Inc,Rahway, NJ,USA; 3 Merck&Co, Inc,Kenilworth,NJ,USA 11:00 99 Lower Ribavirin Exposures in HIV+ Patients That Relapsed to Acute HCV Treatment 1 UnivofColorado,Denver,CO,USA; 2 HarvardSchofPH,Boston, MA,USA; 3 Social&ScientificSystems, Inc.,SilverSpring,MD,USA; 4 UnivofColorado,Aurora,CO,USA; 5 GileadScis, Inc,FosterCity, CA,USA; 6 HarvardMedSch,Boston,MA,USA; 7 DukeUnivSchof Med,Durham,NC,USA 11:15 100 Drug Interaction Studies Between Sofosbuvir/ Velpatasvir and Boosted HIV ARV Regimens Erik Mogalian ; Luisa M. Stamm; Anuoluwapo Osinusi; Gong Shen; Karim Sajwani; John McNally; John Ling; Anita Mathias GileadScis, Inc,FosterCity,CA,USA 11:30 101 EFV Reduced PK of Piperaquine for Malaria Mark Krystal 1 ; DavidWensel 2 ;Yongnian Sun 1 ; Jonathan Davis 2 ; Zhufang Li 1 ;Thomas McDonagh 2 ; Sharon Zhang 1 ; Matt Soars 1 ; Mark Cockett 1 ; for the CombinectinWorking Group 1 Bristol-MyersSquibb,Wallingford,CT,USA; 2 Bristol-Myers Squibb,Waltham,MA,USA Christine E. MacBrayne 1 ; Michael Hughes 2 ; Kimberly M. Hollabaugh 2 ; Jhoanna C. Roa 3 ; Xinhui Chen 4 ; Diana M. Brainard 5 ; RaymondT. Chung 6 ; Susanna Naggie 7 ; Jennifer Kiser 1 ; for the A5327 StudyTeam

Peter Rusert 1 ; Roger Kouyos 2 ; Claus Kadelka 1 ; Hanna Ebner 1 ; Merle Schanz 1 ; Michael Huber 1 ; Dominique L. Braun 2 ; Huldrych F. Günthard 2 ; AlexandraTrkola 3 ; for the the Swiss HIV Cohort Study

1 InstofMedVirology,UnivofZurich,Zurich,Switzerland; 2 UnivHospZurich,Zurich,Switzerland; 3 UnivofZurich,Zurich, Switzerland 10:30 90 Clinical Safety and Pharmacokinetics of IV and SC VRC01, a Broadly Neutralizing mAb

Kenneth H. Mayer 1 ; Kelly Seaton 2 ;Yunda Huang 3 ; Nicole Grunenberg 3 ; John Hural 3 ; Julie Ledgerwood 4 ; Robert Bailer 4 ; Richard A. Koup 4 ; Mary Allen 5 ; Barney Graham 5

1 TheFenway Inst,FenwayHlth,Boston,MA,USA; 2 DukeUniv, Durham,NC,USA; 3 FredHutchinsonCancerRsrCntr,Seattle,WA, USA; 4 VRC,NIAID,NIH,Bethesda,MD,USA; 5 NIAID,NIH,Bethesda, MD,USA 10:45 91 Neutrophil Functions Induced by Gp-120 Specific IgA and IgG; Clues for Immunotherapy Magdalena Sips 1 ; Marina Krykbaeva 1 ; Anne Sophie Dugast 1 ; Fernanda Cerqueira 1 ; Peter Brouckaert 2 ; Galit Alter 1 1 Ragon InstofMGH,MITandHarvard,Cambridge,MA,USA; 2 GhentUniv,Gent,Belgium 11:00 92 Potency and Kinetics of Autologous HIV-1 Neutralizing Antibody Responses During ATI Brenda Salantes ; Benjamin Scheinfeld; Katharine J. Bar UnivofPennsylvania,Philadelphia,PA,USA 11:15 93LB PD-1 Blockade as an Adjunct Therapy to ART and Potential to Destabilize SIV Reservoir 1 EmoryUniv,Atlanta,GA,USA; 2 Dana-FarberCancer Inst,Boston, MA,USA; 3 YerkesNatlPrimateRsrCntr,EmoryUniv,Atlanta,GA, USA 11:30 94 Follicular CTL Accumulate in SIV-Infected Lymph Nodes Due to Immune Activation Costantinos Petrovas 1 ; Sara Ferrando-Martinez 1 ; Amarendra Pegu 1 ; Sarah F. Andrews 1 ; David Ambrozak 1 ; Adrian B. McDermott 1 ; Jason M. Brenchley 2 ; John R. Mascola 3 ; Richard A. Koup 3 1 NIH,Bethesda,MD,USA; 2 FrederickNatlLab forCancerRsr, Frederick,MD,USA; 3 VRC,NIAID,NIH,Bethesda,MD,USA 11:45 95LB Repeated TLR7 Agonist Treatment of SIV+ Monkeys on ART Can Lead to Viral Remission Geetha Mylvaganam 1 ; Sakeenah Hicks 1 ; Benton Lawson 1 ; Melon Nega 1 ;VijayakumarVelu 1 ; Rafi Ahmed 1 ; Gordon J. Freeman 2 ; Rama Amara 3

Wednesday, February 24, 2016 • Oral Sessions

Prevention in HIV+ Ugandan Pregnant Women Richard Kajubi 1 ; Liusheng Huang 2 ; Norah Mwebaza 3 ; Abel Kakuru 4 ; Prasanna Jagannathan 2 ; Philip Rosenthal 2 ; Moses R. Kamya 5 ; Grant Dorsey 2 ; DianeV. Havlir 2 ; Francesca Aweeka 2 1 MakerereUniv,Kampala,,Uganda; 2 UnivofCaliforniaSan Francisco,SanFrancisco,CA,USA; 3 InfectiousDiseasesRsrCollab andMakerereUniv,Kampala,,Uganda; 4 InfectiousDiseasesRsr CollabandMakerereUniv,Kampala,Uganda; 5 MakerereUnivColl ofHlthScis,KAMPALA,Uganda

James B.Whitney 1 ; So-Yon Lim 1 ; Christa E. Osuna 1 ; Srisowmya Sanisetty 1 ;Tiffany L. Barnes 2 ;Tomas Cihlar 2 ; Michael Miller 3 ; Romas Geleziunas 2 ; Joseph Hesselgesser 2 1 Beth IsraelDeaconessMedCntr/Harvard,Boston,MA,USA; 2 GileadSciences, Inc,FosterCity,CA,USA; GileadScis, Inc,Foster City,CA,USA

35

CROI 2016